CHAMPION-AF Clinical Trial

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 3000 participants.

Also called NCT04394546

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Not applicable
Enrolled
  • 3,000 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04394546
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Australia, Belgium, Canada, Denmark, France, Germany, Israel, Italy, Japan, Netherlands, Poland, Saudi Arabia, Spain, Switzerland, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT04394546. Randomized; single masking; primary purpose prevention. Start 2020-10-15 (actual); primary completion 2027-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
CHAMPION-AF Clinical Trial
Acronym
CHAMPION-AF
Condition
Stroke
Condition
Bleeding
Intervention (Device)
WATCHMAN FLX LAAC Device
Intervention (Drug)
Non-Vitamin K Oral Anticoagulant
Lead sponsor
Boston Scientific Corporation (class: industry)

Record details

Record id
cardio:ct-nct04394546
Content hash
c36328544e761d587505c8946e2306d5192e38242b348c7563b4db7e0185a352